Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
3.080
+0.790 (34.50%)
At close: Aug 13, 2025, 4:00 PM
2.850
-0.230 (-7.47%)
Pre-market: Aug 14, 2025, 9:25 AM EDT
Editas Medicine Employees
Editas Medicine had 246 employees as of December 31, 2024. The number of employees decreased by 19 or -7.17% compared to the previous year.
Employees
246
Change (1Y)
-19
Growth (1Y)
-7.17%
Revenue / Employee
$158,134
Profits / Employee
-$962,841
Market Cap
276.95M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
EDIT News
- 1 day ago - Editas Medicine Announces Second Quarter 2025 Results and Business Updates - GlobeNewsWire
- 2 months ago - Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June - GlobeNewsWire
- 3 months ago - I Missed The Quantum Rally - I Won't Miss The Next One - Seeking Alpha
- 3 months ago - Editas Medicine, Inc. (EDIT) BofA Securities 2025 Healthcare Conference (Transcript) - Seeking Alpha
- 3 months ago - Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June - GlobeNewsWire
- 3 months ago - Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting - GlobeNewsWire
- 3 months ago - Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting - GlobeNewsWire
- 3 months ago - Editas Medicine Announces First Quarter 2025 Results and Business Updates - GlobeNewsWire